Business Context and Reporting Period
This Form 8-K Current Report was filed by Silo Pharma, Inc. on April 22, 2021. The filing discloses the entry into a Material Definitive Agreement with Zylö Therapeutics, Inc. (ZTI) to form a joint venture entity named Ketamine Joint Venture, LLC.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or debt metrics. The only financial contribution disclosed is that Silo Pharma shall contribute a "low six figure amount" in cash to the joint venture. No specific liquidity or margin data is provided in this document.
Material Changes and Agreements
- Joint Venture Formation: Silo Pharma and ZTI agreed to form Ketamine Joint Venture, LLC to focus on the clinical development of ketamine using ZTI's Z-pod™ technology.
- Ownership Structure: Silo Pharma will initially own 51% of the joint venture and act as the Manager. ZTI will own 49%. Ownership is capped at 60% for either party.
- Contributions:
- Silo Pharma: Low six-figure cash contribution and expertise from its science advisory board.
- ZTI: Patented technology rights, license to Z-pod™ know-how, ketamine for clinical use, facility access, and expertise.
- Termination: The venture terminates if development milestones are not met within 30 days of the specified date, or at the sole discretion of the Manager (Silo Pharma).
- Future Option: ZTI granted Silo Pharma an exclusive option to form a separate joint venture for psilocybin development on similar terms, expiring 24 months after the effective date.
Guidance, Risks, and Contingencies
The filing does not provide financial guidance or outlook. Key contingencies include:
- Development Milestones: The joint venture is contingent on meeting specific development specifications and milestones.
- Intellectual Property: ZTI must grant a sublicense regarding patented technology licensed from Albert Einstein College of Medicine if needed for the venture or if the technology is sold.
- Confidentiality: Certain portions of the Joint Venture Agreement were omitted from the public filing as they are competitively harmful.
Investor Verification Checklist
- Verify the exact cash amount of the "low six figure" contribution by reviewing the full Joint Venture Agreement (Exhibit 10.1).
- Confirm the specific development milestones and the timeline for the 30-day termination clause.
- Assess the status of the sublicense rights from Albert Einstein College of Medicine required for the venture.
- Monitor the exercise of the exclusive option for the psilocybin joint venture within the 24-month window.